» Articles » PMID: 24004840

Determine TB-LAM Lateral Flow Urine Antigen Assay for HIV-associated Tuberculosis: Recommendations on the Design and Reporting of Clinical Studies

Overview
Journal BMC Infect Dis
Publisher Biomed Central
Date 2013 Sep 6
PMID 24004840
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Detection of the Mycobacterium tuberculosis cell wall antigen lipoarabinomannan (LAM) in urine permits diagnoses of tuberculosis (TB) to be made in HIV-infected patients with advanced immunodeficiency. This can be achieved at the point-of-care within just 30 minutes using the Determine TB-LAM, which is a commercially available, lateral-flow urine 'strip test' assay. The assay has been shown to have useful diagnostic accuracy in patients enrolling in antiretroviral treatment services or in HIV-infected patients requiring admission to hospital medical wards in sub-Saharan Africa. Such patients have high mortality risk and have most to gain from rapid diagnosis of TB and immediate initiation of treatment. However, few studies using this assay have yet been reported and many questions remain concerning the correct use of the assay, interpretation of results, the role of the assay as an add-on test within existing diagnostic algorithms and the types of further studies needed. In this paper we address a series of questions with the aim of informing the design, conduct and interpretation of future studies. Specifically, we clarify which clinical populations are most likely to derive benefit from use of this assay and how patients enrolled in such studies might best be characterised. We describe the importance of employing a rigorous microbiological diagnostic reference standard in studies of diagnostic accuracy and discuss issues surrounding the specificity of the assay in different geographical areas and potential cross-reactivity with non-tuberculous mycobacteria and other organisms. We highlight the importance of careful procedures for urine collection and storage and the critical issue of how to read and interpret the test strips. Finally, we consider how the assay could be used in combination with other assays and outline the types of studies that are required to build the evidence base concerning its use.

Citing Articles

A new rapid lipoarabinomannan urine assay for tuberculosis: a two-centre diagnostic accuracy evaluation in outpatients with and without HIV.

Hamasur B, Okunola A, Sserubiri J, Dube-Nwamba W, Nwamba W, Abdulgader S Res Sq. 2025; .

PMID: 40034451 PMC: 11875286. DOI: 10.21203/rs.3.rs-5386988/v2.


Parallel use of low-complexity automated nucleic acid amplification tests on respiratory samples and stool with or without lateral flow lipoarabinomannan assays to detect pulmonary tuberculosis disease in children.

Olbrich L, Kay A, Bjerrum S, Yang B, Ahsberg J, Nathavitharana R Cochrane Database Syst Rev. 2025; 5:CD016071.

PMID: 39908066 PMC: 11089514. DOI: 10.1002/14651858.CD016071.


Field evaluation of a prototype tuberculosis lipoarabinomannan lateral flow assay on HIV-positive and HIV-negative patients.

Connelly J, Andama A, Grant B, Ball A, Mwebe S, Asege L PLoS One. 2021; 16(7):e0254156.

PMID: 34310609 PMC: 8312950. DOI: 10.1371/journal.pone.0254156.


Elevated Notch ligands in serum are associated with HIV/TB coinfection.

Bermick J, Lincoln P, Allen R, Kunkel S, Schaller M J Clin Tuberc Other Mycobact Dis. 2021; 24:100258.

PMID: 34307905 PMC: 8258674. DOI: 10.1016/j.jctube.2021.100258.


Urine Lipoarabinomannan Testing for All HIV Patients Hospitalized in Medical Wards Identifies a Large Proportion of Patients With Tuberculosis at Risk of Death.

Huerga H, Rucker S, Bastard M, Mpunga J, Amoros Quiles I, Kabaghe C Open Forum Infect Dis. 2021; 8(2):ofaa639.

PMID: 33575422 PMC: 7863865. DOI: 10.1093/ofid/ofaa639.


References
1.
Lawn S, Kerkhoff A, Vogt M, Wood R . Diagnostic and prognostic value of serum C-reactive protein for screening for HIV-associated tuberculosis. Int J Tuberc Lung Dis. 2013; 17(5):636-43. PMC: 3816250. DOI: 10.5588/ijtld.12.0811. View

2.
Lawn S, Kerkhoff A, Wood R . Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis. 2012; 16(5):701. DOI: 10.5588/ijtld.12.0131. View

3.
Lawn S, Wood R . Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis. 2011; 204 Suppl 4:S1159-67. PMC: 3192543. DOI: 10.1093/infdis/jir411. View

4.
Gabay C, Kushner I . Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6):448-54. DOI: 10.1056/NEJM199902113400607. View

5.
Lawn S, Kerkhoff A, Pahlana P, Vogt M, Wood R . Diagnostic yield of tuberculosis using sputum induction in HIV-positive patients before antiretroviral therapy. Int J Tuberc Lung Dis. 2012; 16(10):1354-7. DOI: 10.5588/ijtld.12.0174. View